/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK) of a class action securities lawsuit....
/PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DermTech, Inc. ("DermTech" or the "Company") (NASDAQ: DMTK). Such investors are...
All three healthcare stocks have soared this year, but their share prices may not be sustainable.
Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -13.33% and 4.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its first-quarter 2023 financial...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the release of new survey data...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded,...